Response to Comments: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

This document (Policy A60191) is a response-to-comments notice regarding MolDX LCD L39940 and lists the comment period (08/29/2024–10/12/2024) and the notice/effective dates (notice 06/05/2025, effective 07/20/2025). The provided text contains no clinical coverage indications, limitations, documentation requirements, or frequency limits; extracting those requires reviewing the full LCD L39940 and the response details.

"This document is a Response to Comments for MolDX Local Coverage Determination L39940; comment period 08/29/2024–10/12/2024, notice period begins 06/05/2025, and LCD becomes effective 07/20/2025."

Sign up to see full coverage criteria, indications, and limitations.